ArticleFrontiers in immunology2025
Single-cell transcriptomic analysis reveals a systemic immune dysregulation in intravenous immunoglobulin non-responsive Kawasaki disease.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Identification and functional characterization of ASCC2 as a diagnostic biomarker and immune regulatory hub in Kawasaki disease.Clinical rheumatology · 2026Article
- The Autophagy-Inflammasome Axis as a Molecular Switch: From Persistent Inflammation to Vascular Remodeling in IVIG-Resistant Kawasaki Disease.International journal of molecular sciences · 2026Review
- Comprehensive machine learning for identifying platelet-associated diagnostic biomarkers and immune landscape in Kawasaki disease.Translational pediatrics · 2026Article
- Biomarkers in Primary Systemic Vasculitides: Narrative Review.International journal of molecular sciences · 2026Review
- Preliminary transcriptome profiling of induced pluripotent stem cell-derived hematopoietic stem and progenitor cells in Kawasaki disease.Frontiers in pediatrics · 2026Article
- Intravenous immunoglobulin remodels innate immune cell communication and induces differential autophagy pathways in Kawasaki disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Intravenous immunoglobulin (IVIG) has been established as the first-line treatment for Kawasaki disease (KD). However, 10%-20% of patients are unresponsive, increasing their risk of coronary artery complications. Methods: To elucidate the pathogenesis of IVIG non-responsiveness, we performed single-cell transcriptomic profiling on 24 peripheral blood mononuclear cell (PBMC) samples from responsive and non-responsive KD patients before and after IVIG treatment. Finally, the expression of key cytokines was validated using public bulk RNA-seq data and enzyme-linked immunosorbent assay (ELISA). Results: Non-responders exhibited elevated inflammatory cells, lymphocyte dysfunction, and a stronger inflammatory cytokine response driven by the S100A12-TLR4-MYD88 axis, initiated by Mono_CD14_CD16 cells, which was closely associated with interferon activation. Despite T/NK-cell exhaustion, cytotoxic activity was preserved. All processes appeared to be closely associated with interferon activation. Disrupted Tfh-B-cell coordination was observed alongside plasmablast enrichment. Furthermore, monocytic myeloid-derived suppressor cells (MDSCs) suppressed T-cell function and promoted inflammation. The expression levels of S100A8/A9, S100A12, TNF, TNFSF8/10, and interferon-α were consistent with the transcriptomic data. Conclusions: Our findings reveal the immune landscape in IVIG non-responsive KD and suggest potential targets for alternative therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.